This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Cancer Vaccines: From First-in-Class To Best-in-Class?

1.2 List of Tables

Table 1: Cancer Highlights' Five Pillar Drug Assessment 7Table 2: Breakdown of the Included Cancer Vaccine Drug Pipeline by Stage of Development 28Table 3: Head to Head Target Competition among Cancer Vaccine Drugs 28Table 4: Overview of Drug Target Strategy Themes 33Table 5: Ceased Targets of Cancer Vaccine Drugs 34Table 6: Official Gene Symbol to Target Profle 35Table 7: Mutation Frequencies of Cancer Vaccine Drug Targets 202Table 8: Number of Target-Target Interactions among Targets of Cancer Vaccine Drugs 206Table 9: Available Protein Expression Profiles of Cancer Vaccine Drug Targets 208Table 10: Pathway Summary 216Table 11: Drug Targets without any Identified Assigned Pathways 216Table 12: Pathway Profiles According to BioCarta of Cancer Vaccine Drug Targets 218Table 13: Pathway Profiles According to KEGG of Cancer Vaccine Drug Targets 226Table 14: Pathway Profiles According to NetPath of Cancer Vaccine Drug Targets 243Table 15: First-in-Class Analysis of Drug Target Strategies 247Table 16: Top Competitive Target Strategies of Cancer Vaccine Drugs 247Table 17: First-in-Class and Me-too of Cancer Vaccine Drugs being Marketed 249Table 18: First-in-Class and Me-too of Cancer Vaccine Drugs in Phase III Clinical 250Table 19: The Competition Through Close Mechanistic Approximation Between Phase III Cancer Vaccine Drugs 251Table 20: First-in-Class and Me-too of Cancer Vaccine Drugs in Phase II Clinical Development 252Table 21: The Competition Through Close Mechanistic Approximation Between Phase II Cancer Vaccine Drugs 254Table 22: First-in-Class and Me-too of Cancer Vaccine Drugs in Phase I Clinical Development 255Table 23: The Competition Through Close Mechanistic Approximation Between Phase I Cancer Vaccine Drugs 257Table 24: First-in-Class and Me-too of Cancer Vaccine Drugs in Preclinical Development 258Table 25: The Competition Through Close Mechanistic Approximation Between Preclinical Cancer Vaccine Drugs 259Table 26: Target Strategies of No Data, Suspended or Terminated Cancer Vaccine Drugs 261Table 27: Finding Competitive Profile for Best-in-Class Consideration 263Table 28: Overview of Compound Strategy Competition Among Cancer Vaccine Drugs 388Table 29: Overview of the Competitive Landscape of Small Molecule Based Cancer Vaccine Drugs 390Table 30: Pursued Target Strategies of Small Molecule Drugs Based Cancer Vaccine Drugs 391Table 31: Overview of the Competitive Landscape of Peptide Based Cancer Vaccine Drugs 393Table 32: Competitive Comparison of Target Strategies of Peptide Based Cancer Vaccine Drugs 394Table 33: Pursued Target Strategies of Peptide Based Cancer Vaccine Drugs 395Table 34: Overview of the Competitive Landscape of Protein Based Cancer Vaccine Drugs 397Table 35: Competitive Comparison of Target Strategies of Protein Based Cancer Vaccine Drugs 398Table 36: Pursued Target Strategies of Protein Based Cancer Vaccine Drugs 398Table 37: Overview of the Competitive Landscape of Antibody Based Cancer Vaccine Drugs 400Table 38: Competitive Comparison of Target Strategies of Antibody Based Cancer Vaccine Drugs 401Table 39: Pursued Target Strategies of Antibody Based Cancer Vaccine Drugs 401Table 40: Overview of the Competitive Landscape of Nucleic Acid Based Cancer Vaccine Drugs 404Table 41: Competitive Comparison of Target Strategies of Nucleic Acid Based Cancer Vaccine Drugs 405Table 42: Pursued Target Strategies of Nucleic Acid Based Cancer Vaccine Drugs 405Table 43: Potential Forms of Cell Therapy 407Table 44: Vectors in Gene Therapy 408Table 45: Overview of the Competitive Landscape of Cell Therapy Based Cancer Vaccine Drugs 408Table 46: Competitive Comparison of Target Strategies of Cell Therapy Based Cancer Vaccine Drugs 409Table 47: Pursued Target Strategies of Cell Therapy Based Cancer Vaccine Drugs 409Table 48: Overview of the Competitive Landscape of Gene Therapy Based Cancer Vaccine Drugs 410Table 49: Competitive Comparison of Target Strategies of Gene Therapy Based Cancer Vaccine Drugs 411Table 50: Pursued Target Strategies of Gene Therapy Based Cancer Vaccine Drugs 412Table 51: The Competition Through Close Mechanistic Approximation Among Cancer Vaccine Drugs 414Table 52 Competitive Summary by Indication of Cancer Vaccine Drugs 418Table 53: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Acute Lymphocytic Leukemia 420Table 54: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Acute Myelogenous Leukemia 421Table 55: The Competition through Close Mechanistic Approximation between Acute Myelogenous Leukemia Drugs 421Table 56: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Acute Promyelocytic Leukemia 423Table 57: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Anal Dysplasia 424Table 58: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of B-cell Lymphoma 425Table 59: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Biliary Cancer 426Table 60: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Bladder Cancer 427Table 61: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Bone Cancer 428Table 62: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Brain Cancer 429Table 63: The Competition through Close Mechanistic Approximation between Brain Cancer Drugs 429Table 64: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Breast Cancer 431Table 65: The Competition through Close Mechanistic Approximation between Breast Cancer Drugs 432Table 66: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Cancer (general) 434Table 67: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Cervical Cancer 435Table 68: The Competition through Close Mechanistic Approximation between Cervical Cancer Drugs 437Table 69: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Cervical Dysplasia 438Table 70: The Competition through Close Mechanistic Approximation between Cervical Dysplasia Drugs 439Table 71: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Chronic Myelogenous Leukemia 440Table 72: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Colorectal Adenoma 441Table 73: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Colorectal Cancer 442Table 74: The Competition through Close Mechanistic Approximation between Colorectal Cancer Drugs 443Table 75: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Endometrial Cancer 445Table 76: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Fallopian Tube Cancer 446Table 77: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Gastrointestinal Cancer (general) 447Table 78: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Gastrointestinal Stomach Cancer 448Table 79: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Glioma 449Table 80: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Head and Neck Cancer 450Table 81: The Competition through Close Mechanistic Approximation between Head and Neck Cancer Drugs 450Table 82: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Hematological Cancer (general) 452Table 83: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Leukemia (general) 453Table 84: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Liver Cancer 454Table 85: The Competition through Close Mechanistic Approximation between Liver Cancer Drugs 454Table 86: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Lung Cancer (general) 455Table 87: The Competition through Close Mechanistic Approximation between Lung Cancer (general) Drugs 457Table 88: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Lymphoma (general) 458Table 89: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Melanoma 459Table 90: The Competition through Close Mechanistic Approximation between Melanoma Drugs 460Table 91: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Merkel cell carcinoma 462Table 92: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Mesothelioma 463Table 93: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Myelodysplastic Syndrome 464Table 94: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Myeloma 465Table 95: The Competition through Close Mechanistic Approximation between Myeloma Drugs 465Table 96: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of non-Hodgkin's Lymphoma 466Table 97: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Non-Small Cell Lung Cancer 467Table 98: The Competition through Close Mechanistic Approximation between Non-Small Cell Lung Cancer Drugs 468Table 99: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Oesophageal Cancer 469Table 100: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Osteo Sarcoma 470Table 101: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Ovarian Cancer 471Table 102: The Competition through Close Mechanistic Approximation between Ovarian Cancer Drugs 472Table 103: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Pancreatic Cancer 473Table 104: The Competition through Close Mechanistic Approximation between Pancreatic Cancer Drugs 474Table 105: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Peritoneal Cancer 475Table 106: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Prostate Cancer 476Table 107: The Competition through Close Mechanistic Approximation between Prostate Cancer Drugs 477Table 108: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Radio/chemotherapy-induced Bone Marrow Injury (general) 479Table 109: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Renal Cancer 480Table 110: The Competition through Close Mechanistic Approximation between Renal Cancer Drugs 481Table 111: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Sarcoma (general) 482Table 112: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Skin Cancer (general) 483Table 113: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Small Cell Lung Cancer 484Table 114: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Soft Tissue Sarcoma 485Table 115: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Solid Tumor 486Table 116: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Squamous Cell Carcinoma 487Table 117: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of T-cell Lymphoma 488Table 118: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Thyroid Cancer 489Table 119: Target Strategy Development Profiles of Cancer Vaccine Drugs for the Treatment of Unspecified Cancer Indication 490Table 120: The Competition through Close Mechanistic Approximation between Unspecified Cancer Indication Drugs 491Table 121: Target Strategy Development Profiles of Cancer Vaccine Drugs as Vaccine adjunct 492Table 122: Competitive Summary by Company of Cancer Vaccine Drug Development 493Table 123: Summary Table of Corporate Changes in the Competitive Landscape of Cancer Vaccine Drug Development 496Table 124: The Worst Ranking and the Highest Populated Level for Each of the 15 Ranking Parameters 499Table 125: Example of a Competitive Fall-Out Table (Targeting TERT Modified) 505Table 126: AC Immune's Included Cancer Vaccine Drugs and Competitive Fall-Out 508Table 127: Adaptimmune's Included Cancer Vaccine Drugs and Competitive Fall-Out 512Table 128: Advaxis' Included Cancer Vaccine Drugs and Competitive Fall-Out 518Table 129: Agenus' Included Cancer Vaccine Drugs and Competitive Fall-Out 525Table 130: Aida Pharmaceuticals' Included Cancer Vaccine Drugs and Competitive Fall-Out 529Table 131: AlphaVax's Included Cancer Vaccine Drugs and Competitive Fall-Out 533Table 132: Amgen's Included Cancer Vaccine Drugs and Competitive Fall-Out 539Table 133: Anza Therapeutics' Included Cancer Vaccine Drugs and Competitive Fall-Out 543Table 134: Argos Therapeutics' Included Cancer Vaccine Drugs and Competitive Fall-Out 546Table 135: Astellas' Included Cancer Vaccine Drugs and Competitive Fall-Out 549Table 136: AstraZeneca's Included Cancer Vaccine Drugs and Competitive Fall-Out 552Table 137: Bavarian Nordic's Included Cancer Vaccine Drugs and Competitive Fall-Out 556Table 138: Bellicum Pharmaceuticals' Included Cancer Vaccine Drugs and Competitive Fall-Out 561Table 139: Biogen Idec's Included Cancer Vaccine Drugs and Competitive Fall-Out 565Table 140: BioNTech's Included Cancer Vaccine Drugs and Competitive Fall-Out 568Table 141: BioSante's Included Cancer Vaccine Drugs and Competitive Fall-Out 572Table 142: Biostar's Included Cancer Vaccine Drugs and Competitive Fall-Out 576Table 143: BioVex's Included Cancer Vaccine Drugs and Competitive Fall-Out 579Table 144: BreakThrough Therapeutics' Included Cancer Vaccine Drugs and Competitive Fall-Out 582Table 145: Bristol-Myers Squibb's Included Cancer Vaccine Drugs and Competitive Fall-Out 585Table 146: Cancer Advances' Included Cancer Vaccine Drugs and Competitive Fall-Out 588Table 147: Cancer Research Technology's Included Cancer Vaccine Drugs and Competitive Fall-Out 592Table 148: Celldex Therapeutics' Included Cancer Vaccine Drugs and Competitive Fall-Out 599Table 149: Center of Molecular Immunology's Included Cancer Vaccine Drugs and Competitive Fall-Out 604Table 150: CG Therapeutics' Included Cancer Vaccine Drugs and Competitive Fall-Out 608Table 151: Cosmo Pharmaceuticals' Included Cancer Vaccine Drugs and Competitive Fall-Out 613Table 152: CreaGene's Included Cancer Vaccine Drugs and Competitive Fall-Out 617Table 153: CSL's Included Cancer Vaccine Drugs and Competitive Fall-Out 621Table 154: CureVac's Included Cancer Vaccine Drugs and Competitive Fall-Out 624Table 155: Dainippon Sumitomo Pharma's Included Cancer Vaccine Drugs and Competitive Fall-Out 629Table 156: Dendreon's Included Cancer Vaccine Drugs and Competitive Fall-Out 635Table 157: DeveloGen's Included Cancer Vaccine Drugs and Competitive Fall-Out 642Table 158: Eisai's Included Cancer Vaccine Drugs and Competitive Fall-Out 645Table 159: Eli Lilly's Included Cancer Vaccine Drugs and Competitive Fall-Out 648Table 160: EntreMed's Included Cancer Vaccine Drugs and Competitive Fall-Out 651Table 161: Epeius Biotechnologies' Included Cancer Vaccine Drugs and Competitive Fall-Out 654Table 162: Etubics' Included Cancer Vaccine Drugs and Competitive Fall-Out 659Table 163: Galena Biopharma's Included Cancer Vaccine Drugs and Competitive Fall-Out 667Table 164: Generex's Included Cancer Vaccine Drugs and Competitive Fall-Out 673Table 165: GenOdyssee Pharmaceuticals' Included Cancer Vaccine Drugs and Competitive Fall-Out 678Table 166: Genticel's Included Cancer Vaccine Drugs and Competitive Fall-Out 682Table 167: Geron's Included Cancer Vaccine Drugs and Competitive Fall-Out 686Table 168: GlaxoSmithKline's Included Cancer Vaccine Drugs and Competitive Fall-Out 694Table 169: Gliknik's Included Cancer Vaccine Drugs and Competitive Fall-Out 701Table 170: GlobeImmune's Included Cancer Vaccine Drugs and Competitive Fall-Out 705Table 171: Gradalis' Included Cancer Vaccine Drugs and Competitive Fall-Out 710Table 172: Heat Biologics' Included Cancer Vaccine Drugs and Competitive Fall-Out 713Table 173: Hemispherx Biopharma's Included Cancer Vaccine Drugs and Competitive Fall-Out 716Table 174: Hoffmann-La Roche's Included Cancer Vaccine Drugs and Competitive Fall-Out 719Table 175: Ichor Medical Systems' Included Cancer Vaccine Drugs and Competitive Fall-Out 723Table 176: Idera Pharmaceuticals' Included Cancer Vaccine Drugs and Competitive Fall-Out 728Table 177: immatics biotechnologies' Included Cancer Vaccine Drugs and Competitive Fall-Out 732Table 178: ImmunoCellular Therapeutics' Included Cancer Vaccine Drugs and Competitive Fall-Out 735Table 179: ImmunoFrontier's Included Cancer Vaccine Drugs and Competitive Fall-Out 739Table 180: Immunotope's Included Cancer Vaccine Drugs and Competitive Fall-Out 744Table 181: Immunovaccine's Included Cancer Vaccine Drugs and Competitive Fall-Out 748Table 182: Inovio's Included Cancer Vaccine Drugs and Competitive Fall-Out 752Table 183: Intracel's Included Cancer Vaccine Drugs and Competitive Fall-Out 758Table 184: Introgen Therapeutics' Included Cancer Vaccine Drugs and Competitive Fall-Out 761Table 185: ISA Pharmaceuticals' Included Cancer Vaccine Drugs and Competitive Fall-Out 764Table 186: Jennerex Biotherapeutics' Included Cancer Vaccine Drugs and Competitive Fall-Out 769Table 187: Johnson & Johnson's Included Cancer Vaccine Drugs and Competitive Fall-Out 774Table 188: KAEL-GemVax's Included Cancer Vaccine Drugs and Competitive Fall-Out 778Table 189: Lipotek's Included Cancer Vaccine Drugs and Competitive Fall-Out 782Table 190: Mannkind's Included Cancer Vaccine Drugs and Competitive Fall-Out 786Table 191: MediGene's Included Cancer Vaccine Drugs and Competitive Fall-Out 791Table 192: Menarini's Included Cancer Vaccine Drugs and Competitive Fall-Out 796Table 193: Merck KGaA's Included Cancer Vaccine Drugs and Competitive Fall-Out 800Table 194: Micromet's Included Cancer Vaccine Drugs and Competitive Fall-Out 803Table 195: MolMed's Included Cancer Vaccine Drugs and Competitive Fall-Out 806Table 196: Mologen's Included Cancer Vaccine Drugs and Competitive Fall-Out 809Table 197: Momotaro-Gene's Included Cancer Vaccine Drugs and Competitive Fall-Out 813Table 198: Nemod Biotherapeutics' Included Cancer Vaccine Drugs and Competitive Fall-Out 817Table 199: Neovacs' Included Cancer Vaccine Drugs and Competitive Fall-Out 821Table 200: NIH's Included Cancer Vaccine Drugs and Competitive Fall-Out 825Table 201: Non-industrial source's Included Cancer Vaccine Drugs and Competitive Fall-Out 830Table 202: Northwest Biotherapeutics' Included Cancer Vaccine Drugs and Competitive Fall-Out 839Table 203: NovaRx's Included Cancer Vaccine Drugs and Competitive Fall-Out 842Table 204: OncoMune's Included Cancer Vaccine Drugs and Competitive Fall-Out 845Table 205: OncoTherapy Science's Included Cancer Vaccine Drugs and Competitive Fall-Out 848Table 206: Oncothyreon's Included Cancer Vaccine Drugs and Competitive Fall-Out 852Table 207: Oncovir's Included Cancer Vaccine Drugs and Competitive Fall-Out 859Table 208: Onyvax's Included Cancer Vaccine Drugs and Competitive Fall-Out 862Table 209: Orchestra Therapeutics' Included Cancer Vaccine Drugs and Competitive Fall-Out 865Table 210: Oxford BioMedica's Included Cancer Vaccine Drugs and Competitive Fall-Out 869Table 211: Pepscan Therapeutics' Included Cancer Vaccine Drugs and Competitive Fall-Out 874Table 212: Peptagen's Included Cancer Vaccine Drugs and Competitive Fall-Out 878Table 213: Pfizer's Included Cancer Vaccine Drugs and Competitive Fall-Out 882Table 214: PharmaForm's Included Cancer Vaccine Drugs and Competitive Fall-Out 886Table 215: Pharmexa's Included Cancer Vaccine Drugs and Competitive Fall-Out 891Table 216: Progenics Pharmaceuticals' Included Cancer Vaccine Drugs and Competitive Fall-Out 899Table 217: Protherics' Included Cancer Vaccine Drugs and Competitive Fall-Out 904Table 218: Radient Pharmaceuticals' Included Cancer Vaccine Drugs and Competitive Fall-Out 907Table 219: Receptor BioLogix's Included Cancer Vaccine Drugs and Competitive Fall-Out 911Table 220: responsif's Included Cancer Vaccine Drugs and Competitive Fall-Out 915Table 221: Sanofi's Included Cancer Vaccine Drugs and Competitive Fall-Out 918Table 222: Sarepta Therapeutics' Included Cancer Vaccine Drugs and Competitive Fall-Out 922Table 223: Scancell's Included Cancer Vaccine Drugs and Competitive Fall-Out 926Table 224: Shionogi's Included Cancer Vaccine Drugs and Competitive Fall-Out 929Table 225: TapImmune's Included Cancer Vaccine Drugs and Competitive Fall-Out 932Table 226: Therion Biologics' Included Cancer Vaccine Drugs and Competitive Fall-Out 936Table 227: Transgene's Included Cancer Vaccine Drugs and Competitive Fall-Out 943Table 228: United Biomedical's Included Cancer Vaccine Drugs and Competitive Fall-Out 947Table 229: Vaccinex's Included Cancer Vaccine Drugs and Competitive Fall-Out 950Table 230: Vaxil BioTherapeutics' Included Cancer Vaccine Drugs and Competitive Fall-Out 955Table 231: Vaximm's Included Cancer Vaccine Drugs and Competitive Fall-Out 959Table 232: Vaxon Biotech's Included Cancer Vaccine Drugs and Competitive Fall-Out 963Table 233: Vectura's Included Cancer Vaccine Drugs and Competitive Fall-Out 967Table 234: Vical's Included Cancer Vaccine Drugs and Competitive Fall-Out 971Table 235: Viragen's Included Cancer Vaccine Drugs and Competitive Fall-Out 977Table 236: Virionics' Included Cancer Vaccine Drugs and Competitive Fall-Out 980Table 237: ViroMed's Included Cancer Vaccine Drugs and Competitive Fall-Out 984Table 238: Zensun's Included Cancer Vaccine Drugs and Competitive Fall-Out 988Table 239: Zydus Cadila's Included Cancer Vaccine Drugs and Competitive Fall-Out 992

To order this report: Drug_and_Medication Industry: Cancer Vaccines: From First-in-Class to Best-in-Class?

Contact Clare: clare@reportlinker.com US:(339) 368 6001 Intl:+1 339 368 6001

SOURCE Reportlinker

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
3 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,014.80 -24.69 -0.14%
S&P 500 1,988.63 -3.74 -0.19%
NASDAQ 4,537.2540 +5.15 0.11%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs